Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 11, 2014, Pages 4251-4256

  Wang, Shan ^a   Kollipara, Rahul K ^a   Srivastava, Nishi ^a   Li, Rui ^b   Ravindranathan, Preethi ^b   Hernandez, Elizabeth ^b   Freeman, Eva ^b   Humphries, Caroline G ^a   Kapur, Payal ^b   Lotan, Yair ^b   Fazli, Ladan ^c   Gleave, Martin E ^c   Plymate, Stephen R ^d   Raj, Ganesh V ^b   Hsieh, Jer Tsong ^b,e   Kittler, Ralf ^a,b,e,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; ENZYME INHIBITOR; TRANSCRIPTION FACTOR ERG; UBIQUITIN SPECIFIC PEPTIDASE 9 X LINKED; UNCLASSIFIED DRUG; WP 1130;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; ENZYMATIC DEGRADATION; ENZYME BINDING; ENZYME INHIBITION; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; UBIQUITINATION;

ANIMALS; CELL PROLIFERATION; ENDOPEPTIDASES; HELA CELLS; HUMANS; MALE; MICE; NITRILES; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PYRIDINES; RNA INTERFERENCE; UBIQUITINATION;

EID: 84896502088     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322198111     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
2. Tomlins SA, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644-648. (Pubitemid 41528150)
3. Mehra R, et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20(5):538-544. (Pubitemid 46631996)
4. Demichelis F, et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596-4599. (Pubitemid 47037039)
5. Cai C, Wang H, Xu Y, Chen S, Balk SP (2009) Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69(15):6027-6032.
6. Tomlins SA, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448(7153):595-599. (Pubitemid 47206938)
7. Klezovitch O, et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105(6):2105-2110. (Pubitemid 351439472)
8. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8(7):497-511.
9. Carver BS, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5):619-624.
10. Zong Y, et al. (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 106(30):12465-12470.
11. Attard G, et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69(7): 2912-2918.
12. Chen Y, et al. (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 19(8):1023-1029.
13. Chng KR, et al. (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 31(12):2810-2823.
14. Yu J, et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17(5):443-454.
15. Taya S, et al. (1998) The Ras target AF-6 is a substrate of the fam deubiquitinating enzyme. J Cell Biol 142(4):1053-1062. (Pubitemid 28402059)
16. Schwickart M, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463(7277):103-107.
17. Bartholomeusz GA, et al. (2007) Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109(8): 3470-3478. (Pubitemid 46572537)
18. Kapuria V, et al. (2010) Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 70(22):9265-9276.
19. Sun H, et al. (2011) Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 117(11):3151-3162.
20. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM (2013) Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol 10(8):483-487.
21. Brenner JC, et al. (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5):664-678.
22. Hollenhorst PC, et al. (2011) Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 25(20):2147-2157.
23. Shao L, et al. (2012) Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 18(24):6648-6657.
24. Gustavsson H, Wang W, Jennbacken K, Welén K, Damber JE (2009) ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int 104(11): 1786-1790.
25. Zhang X, et al. (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 6(11):e27970.